Anhydrous BTK Inhibitor Polymorphs for Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need to provide a solid state form of N-(3-(6-Amino-5-(2-(N-methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide that possesses physicochemical properties allowing for a reliable production of a safe and efficacious drug product, as existing knowledge does not account for crystalline forms of this compound, which can affect solubility, stability, and bioavailability.
Innovation Solution
The development of three crystalline forms (Forms A, B, and C) of N-(3-(6-Amino-5-(2-(N-methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide, characterized by specific XRPD patterns and thermal profiles, which are useful in treating diseases ameliorated by Bruton's tyrosine kinase inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no crystalline form information is provided for the compound, then the drug development process lacks critical solid state data, but this results in inability to predict and optimize solubility, stability, and bioavailability
Solution Approach 1:
The patent performs preliminary characterization of crystalline forms before drug development proceeds, identifying Forms I, II, and III with their distinct properties. This advance knowledge allows prediction and optimization of solubility, stability, and bioavailability parameters throughout the drug development process.
Solution Approach 2:
The patent systematically varies crystallization parameters (solvent type, temperature, pH) to generate different crystalline forms with distinct physical and chemical properties. Form I, Form II, and Form III exhibit different solubility, stability, and dissolution rates due to their unique crystal lattice arrangements.
2Manufacturing precision
If multiple crystalline forms exist but are not identified, then the compound may have optimal therapeutic properties, but the occurrence of unknown crystalline forms during manufacture can have a significant impact on product quality and safety
Solution Approach 1:
The patent employs X-ray powder diffraction (XRPD) patterns as unique fingerprints to identify and differentiate crystalline forms. Each form (I, II, III) has a distinct XRPD pattern that allows for reliable detection and control during manufacturing, ensuring product consistency and preventing unintended form conversion.
Solution Approach 2:
The patent establishes characterization methods and stability studies that provide feedback on crystalline form identity and purity throughout manufacturing and storage. This enables real-time monitoring and control to prevent formation of undesired polymorphs that could affect product quality.
3Ease of manufacture
If crystalline forms are not characterized early in development, then development time is reduced initially, but understanding which crystalline forms are possible allows researchers to maximize desired properties such as solubility, formulation properties, and shelf life
Solution Approach 1:
The patent performs comprehensive crystalline form characterization early in the drug development process, identifying all possible polymorphs and their properties before formulation development begins. This preliminary work accelerates subsequent formulation efforts by providing a known set of candidates with characterized properties.
Solution Approach 2:
The patent systematically explores crystallization conditions to identify forms with optimal properties for different formulation needs. Form I, II, and III can be selected based on desired characteristics such as solubility, stability, or dissolution rate, enabling optimized formulation development.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These crystalline forms enhance the stability, solubility, and bioavailability of the drug, providing effective treatment options for inflammatory and autoimmune disorders, pulmonary and respiratory tract inflammation, and other BTK-mediated conditions.
Implementation Method 1
Polymorphism denotes the existence of more than one crystalline form of a substance. Crystalline forms occur where the same composition of matter crystallizes in a different lattice arrangement resulting in different thermodynamic properties and stabilities specific to the particular crystalline form.
Implementation Method 2
Crystalline forms (Forms A, B, and C) of N-(3-(6-Amino-5-(2-(N-methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide, characterized by specific XRPD patterns and thermal profiles
Implementation Method 3
characterized by specific XRPD patterns and thermal profiles
Data Source
AI summary
This application relates to various anhydrous crystalline forms N-(3-(6-Amino-5-(2-(N-methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide, as well as compositions, method of making and methods of using the same. These crystalline forms are useful in the treatment of diseases and disorders which are typically ameliorated by the inhibition of BTK. Such diseases and disorders may include inflammatory and autoimmune disorders and pulmonary and respiratory tract inflammation.